Abstract
Coronavirus 2 (SARS-CoV-2), which started in December 2019 in Wuhan province in China and caused serious respiratory infections in humans, was accepted as a pandemic on March 11, 2020. The disease from SARS-CoV-2 is called COVID-19. In a short period of five months, approximately 4 million people were infected and 300 thousand people died from this disease. To date, no specific therapeutic agents or prophylaxis for COVID-19 are available, so it is among the passive immunization treatment options with the plasma of patients who recover from the disease. Convalescent plasma therapy has been used in epidemic periods in the past and has been shown to be effective. Neutralizing antibodies in plasma contributes to recovery by inactivating the virus. In the literature, there are 4 publications presenting a total of 21 patients receiving convalescent plasma. They reported that the patients benefited from the treatment of convalescent plasma and that there were no complications. Studies have been initiated about convalescent plasma all over the world and their results are interestedly awaited.
Keywords: Convalescent plasma, COVID 19, Immune plasma, SARS-CoV-2
References
- Novel Coronavirus Pneumonia Emergency Response Epidemiology Team The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41:145-51.
- Yin S, Peng Y, Ren Y, Hu M, Tang L, Xiang Z, et al. The implications of preliminary screening and diagnosis: Clinical characteristics of 33 mild patients with SARS-CoV-2 infection in Hunan, China. J Clin Virol 2020;128:104397.
- Gasparyan AY, Misra DP, Yessirkepov M, Zimba O. Perspectives of Immune Therapy in Coronavirus Disease 2019. J Korean Med Sci 2020;35:e176.
- Rojas M, Rodriguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev 2020;19:102554.
- Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med 2020;26:453-5.
- Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. T J Clin Invest 2020;130:1545-8.
- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. BMJ 2020;3:16. Doi: 10.1101/2020.03.16.20036145
- Investigational covid-19 convalescent plasma—emergency INDs. https://www.fda. gov/ vaccines-blood-biologics/investigational-newdrug-ind-or-device-exemption-ideprocesscber/ investigational-covid19-convalescent-plasma-emergency-inds
- WHO. Rolling updates on corona virüs disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Updated March 17, 2020 Accessed March 18, 2020.
- Turkish Ministry of Health Immune Plasma Guidelines, 2020. Available from: URL: https://dosyamerkez.saglik.gov.tr/Eklenti/37163,covid-19-immun-plazma-rehberi-12-nisan-2020-sonv1-ti-neopdfpdf.pdf?0&_tag1=D61DB6867EF68EE9A7FE73C870D9BBA04AACC05C
- McGonagle D, Sharif K, O’Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmu-nity rev 2020;19:102537.
- COVID-19 and Convalescent Plasma: Frequently Asked Questions, ASH Webinar on the Use of Convalescent Plasma During COVID-19, hematology.zoom.us/webinar/register/WN_iSKRIhdeSPe8YEuu0C37Vg 8 May, 2020.
- Zhang B, Liu S, Tan T,Huang W, Dong Y, Chen L, et al. Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection. Chest 2020;S0012-3692(20)30571-7.
- Liu BP, Chong EY, Cheung FW, Duan JA, Che CT, Liu WK. Tangutorine induces p21 expression and abnormal mitosis in human colon cancer HT-29 cells. Biochem Pharmacol 2005;70:287-99.
- Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020;323:1582-9.
- Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Beak YJ, et al. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci 2020 ;35:e149.
Copyright and license
Copyright © 2020 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.
